FindTrial
Sign In

IMB-1018972

DRUG4 trials

Sponsors

Imbria Pharmaceuticals, Inc.

Conditions

Coronary Artery DiseaseDiabetic CardiomyopathiesHFpEF - Heart Failure With Preserved Ejection FractionIschemiaNon-obstructive Hypertrophic CardiomyopathyRefractory AnginaType 2 Diabetes

Phase 2

A Study to Evaluate the Safety, Tolerability, and Efficacy of IMB-1018972 in Patients With Refractory Angina
WithdrawnNCT04306237
Imbria Pharmaceuticals, Inc.Refractory Angina
Start: 2020-05-01End: 2025-04-30Updated: 2025-11-10
Exploratory Study on the Safety, Tolerability, and Pharmacodynamics of IMB-1018972 in Subjects With Angina Due to Obstructive Coronary Artery Disease (IMPROVE-Ischemia)
CompletedNCT04826172
Imbria Pharmaceuticals, Inc.Coronary Artery Disease, Ischemia
Start: 2021-04-23End: 2023-09-21Updated: 2024-04-23
A Study to Evaluate the Safety, Tolerability, and Efficacy of IMB-1018972 in Patients With Non-obstructive Hypertrophic Cardiomyopathy Trial
CompletedNCT04826185
Imbria Pharmaceuticals, Inc.Non-obstructive Hypertrophic Cardiomyopathy
Start: 2021-06-14End: 2023-09-18Updated: 2024-04-23
IMPROVE-DiCE: Study to Evaluate Effect of IMB-1018972 on Cardiac Energetics in T2DM & Obesity (Pt 1) With HFpEF (Pt 2)
CompletedNCT04826159
Imbria Pharmaceuticals, Inc.Diabetic Cardiomyopathies, HFpEF - Heart Failure With Preserved Ejection Fraction, Type 2 Diabetes
Start: 2021-04-21End: 2024-08-06Updated: 2025-06-29

Related Papers

IMPROVE-DiCE, a 2-Part, Open-Label, Phase 2a Trial Evaluating the Safety and Effectiveness of Ninerafaxstat in Patients With Cardiometabolic Syndromes.
2025-12-18
IMPROVE-DiCE, a 2-Part, Open-Label, Phase 2a Trial Evaluating the Safety and Effectiveness of Ninerafaxstat in Patients With Cardiometabolic Syndromes.
Open Access CRIS of the University of Bern2025-12-18